title: Horsetail mixture on rheumatoid arthritis and its regulation on TNF-α and IL-10.
abstract: Taking autoimmune inflammation of rheumatoid arthritis as entry point, this paper discussed the clinical effect of horsetail mixture on rheumatoid arthritis (RA) and its mechanism. A total of 60 cases of patients with RA were randomly divided into experimental group and control group using randomized controlled trial. We observed its biochemistry, TNF-α and IL-10 before and after treatment, and then systematically assessed the clinical effect of horsetail on RA. Results showed that the total effective rate of experimental group was 80%, while that of control group was 16.67%. After statistical treatment, the differences between two groups were significant (p<0.01). Comparison of the difference value of TNF-α (p<0.05) and IL-0.05 in serum between groups before and after treatment, there were significant differences. Comparison of CRP within group before and after treatment was significantly different (p<0.05), while comparison of CRP between groups was not significantly different (p>0.05). Comparison of ESR and RF within group before and after treatment was significantly different (p<0.01), and comparison of them between groups was also significantly different (p<0.05). Comparison of difference values within group before and after treatment were also significantly different (p<0.01). It was concluded that horsetail mixture has remarkable curative effect on rheumatoid arthritis, and its clinical application is safe and reliable. It has obvious down regulatory effect on cell factor TNF-α related to RA, that is, it can down regulate the level of pre-inflammatory factor TNF-α as well as the level of anti-inflammatory factor IL-10. Therefore, it is considered that the regulating effect of horsetail mixture on TNF-α and IL-10 is one of the mechanisms of its treatment on RA.
authors.affiliation: Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China / Department of Kidney Transplantation, People's Hospital of Zhengzhou, Zhengzhou, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Jiang
authors.affiliation: Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
authors.forename: Qingshan
authors.initials: Q
authors.lastname: Qu
authors.affiliation: Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Li
authors.affiliation: Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
authors.forename: Shuzhai
authors.initials: S
authors.lastname: Miao
authors.affiliation: Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
authors.forename: Xing
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
authors.forename: Wenli
authors.initials: W
authors.lastname: Cai
mesh_terms: D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D002097:C-Reactive Protein / Q000032:analysis; D004365:Drugs, Chinese Herbal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*
chemical_list: D004365:Drugs, Chinese Herbal; C508609:IL10 protein, human; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D002097:C-Reactive Protein